FDA grants priority review to Nexavar

08/21/2007 | Boston Globe (tiered subscription model), The

Nexavar, a kidney cancer drug jointly developed by Bayer AG and Onyx Pharmaceuticals, has been granted priority review by the FDA for use as a treatment for hepatocellular carcinoma, the most common form of liver cancer. Nexavar already is approved in many countries to treat advanced kidney cancer.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY